{"id":"lurasidone-hc1","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Akathisia"},{"rate":"8-12","effect":"Somnolence"},{"rate":"5-10","effect":"Parkinsonism"},{"rate":"8-10","effect":"Nausea"},{"rate":"5-8","effect":"Agitation"},{"rate":"5-7","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lurasidone acts as an antagonist at dopamine D2 receptors and serotonin 5-HT7 receptors, with high binding affinity and selectivity for these targets. This dual antagonism helps modulate neurotransmitter activity implicated in psychotic and mood disorders. The drug has minimal affinity for other receptors, which may contribute to a favorable side-effect profile compared to first-generation antipsychotics.","oneSentence":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:47.162Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder depression"},{"name":"Major depressive disorder (adjunctive treatment)"}]},"trialDetails":[{"nctId":"NCT00789698","phase":"PHASE3","title":"Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-12","conditions":"Chronic Schizophrenia","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lurasidone HC1","genericName":"Lurasidone HC1","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lurasidone HC1 is used to treat chronic schizophrenia. It is compared to Quetiapine XR in clinical trials for this indication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}